华海药业: 浙江华海药业股份有限公司关于“华海转债”2025年跟踪评级结果的公告

Group 1 - The company's main credit rating remains "AA" with a stable outlook [1] - The tracking credit rating for the "Huahai Convertible Bond" is also maintained at "AA" [1] - The rating was conducted by Shanghai New Century Credit Rating Investment Service Co., Ltd. based on a comprehensive analysis of the company's industry and operational status [1] Group 2 - The previous credit rating results for the company and the convertible bond were both "AA" as of June 28, 2024 [1] - The announcement is made in accordance with the relevant regulations of the Securities Issuance Registration Management Measures and the Shanghai Stock Exchange Listing Rules [1] - The announcement was issued by the Board of Directors of Zhejiang Huahai Pharmaceutical Co., Ltd. on June 27, 2025 [2]